



Professor Seng Gee Lim, FRACP, FRCP, FAMS, MD, is the Chairman of the Singapore Hepatitis Conference and was recently the Chairman of the Asia Pacific Association for Study of the Liver (APASL) Liver Week 2013 Congress. He has been appointed in 2014 to the governing council of the International Association for Study of Liver (IASL). He graduated in 1980 from Monash Medical School and trained at the Alfred Hospital, Melbourne, Australia. He worked as a research fellow at the Royal Free Hospital, London, UK where he completed his research MD. He then joined the National University Hospital, Singapore in 1996, where he was Chief of Gastroenterology and Hepatology from 2002 – 2011 and is now Director of Hepatology. He is Adjunct Principal Investigator at the Institute of Molecular and Cell Biology, Biopolis, ASTAR, Singapore. He is a Fellow of the Royal Australasian College of Physicians, Royal College of Physicians of London, and Fellow of the Academy of Medicine, Singapore. He is a member of the editorial boards for Liver International, Journal of Viral Hepatitis, Hepatology International, Alimentary Pharmacology and Therapeutics, Evidence Based Internal Medicine Solutions, Open Tropical Medicine Journal. He has served on all the National Research Grant Committees in Singapore and completed a 3 year term as an abstract reviewer for the American Association for Study of Liver Disease. He is also on the advisory board of Gilead Sciences, Novartis Pharmaceuticals, Bristol Myers Pharmaceuticals, Merck Sharpe and Dohme Pharmaceuticals, Pfizer Pharmaceuticals, Janssen Pharmaceuticals, Abbvie, Boehringer Ingelheim and Archillion Pharmaceuticals. He was recently the chairman of the Evidence Based Medicine Subcommittee at National University Hospital, and chairman of the Asia Pacific Evidence Based Medicine Workshop. Professor Lim has research interests in clinical trials of new treatments for chronic hepatitis B and C (where he has been principal investigator in many clinical trials). He has a particular interest in translational research in viral hepatitis, involving molecular biology and immunology of hepatitis, and runs an active laboratory investigating hepatitis B lifecycle events. In addition he has a diversity of clinical research interests ranging from cost-effective analysis to health related quality of life analysis and treatment outcomes. Professor Lim has over 180 peer review publications and has been awarded over \$8 million in grant funding for his research. He has won a \$25 million National grant in 2015 to investigate eradication of HBV.